ArticleJournal of the American Society of Nephrology : JASN2026
Assessment of Medicare Advantage Stars Measures: Impact on Kidney Care Quality and Future Opportunities.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Centers for Medicare & Medicaid Services uses the Star quality program to evaluate Medicare Advantage (Medicare Part C) care quality. Since the 21st Century Cures Act, ESRD enrollment within Medicare has shifted from <30% in 2021 with Medicare Advantage to more than 50% in 2024. Given this influx and growing CKD prevalence, evaluating how Stars measures shape kidney care has significant population health implications. The American Society of Nephrology Quality Committee convened a working group to assess the 2026 Medicare Part C and D Stars quality measures. Measures were reviewed using a modified American College of Physicians Measure Review Criteria, which evaluates measure importance, appropriateness, evidence base, specifications, and feasibility, and Stars measures evaluating nonclinical outcomes were excluded ( e.g ., customer service). The American Society of Nephrology committee evaluated 25 (of 45) Star quality measures that were directly related to clinical outcomes. The committee assessment identified 13 high-validity Star measures that monitored care related to diabetes, hypertension, and care transitions, as well as 12 medium-validity measures that evaluated preventive care and other chronic care areas. The appropriateness and clinical evidence base of Star measures were generally strong but weaker in patients with kidney failure. The committee noted concerns with ten Stars measures that may exclude patients with kidney failure. Only one measure captured guideline-directed kidney care (albuminuria screening in patients with diabetes). No Stars measures captured other guideline-directed recommendations, such as CKD screening and risk stratification, nephrology referral, use of kidney pharmacotherapies, CKD education, or preemptive kidney transplantation referral. The Medicare 2026 Part C and D Stars measures represent a missed opportunity to align care measures and guideline-directed kidney care to improve outcomes, reduce costs, and advance high-value care for the millions of Americans living with kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.